Pharmaceutical composition comprising GLP-1 receptor agonist, GIP / GLP-1 receptor agonist and / or GLP-1 / GIP / GCG receptor triple agonist

Sustained-release microspheres using fluid oils and surfactants or polyhydric alcohols address stability and absorption issues in GLP-1 receptor agonist compositions, offering improved bioavailability and reduced injection frequency for GLP-1 receptor agonists, GIP/GLP-1 receptor agonists, and GLP-1/GIP/GCG receptor triple agonists.

WO2024248530A1PCT designated stage expired Publication Date: 2024-12-05AULBIO CO LTD
View PDF 16 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007467
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-16
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current pharmaceutical compositions containing GLP-1 receptor agonists, GIP/GLP-1 receptor agonists, and GLP-1/GIP/GCG receptor triple agonists face challenges with enzymatic degradation, insufficient absorption, and first-pass metabolism, necessitating injection administration, which is inconvenient and has stability issues in aqueous carriers.

Method used

Development of sustained-release microspheres using a fluid oil carrier, such as coconut or sesame oil, combined with a surfactant like Poloxamer 188 or a polyhydric alcohol like ethylene glycol, to maintain long-term stability and enhance bioavailability, allowing for a single injection with improved dissolution characteristics.

Benefits of technology

The microsphere compositions provide long-term stability and increased bioavailability, reducing the frequency of injections and improving patient convenience by maintaining therapeutic levels for extended periods with enhanced drug absorption.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007467_05122024_PF_FP_ABST
    Figure KR2024007467_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a pharmaceutical composition comprising: microspheres including at least one selected from among a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist; and at least one pharmaceutically acceptable first carrier selected from the group consisting of a fluid oil including a fatty acid ester, a surfactant, and a polyhydric alcohol. In the pharmaceutical composition, the stability of the microspheres is maintained for a long period of time in a suspension formulation, and thus the microspheres stored for a long period of time exhibit excellent dissolution characteristics. In addition, the pharmaceutical composition exhibits the effects of increasing bioavailability and reducing dosage.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition comprising a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and / or a GLP-1 / GIP / GCG receptor triple agonist

[0001] The present invention relates to a pharmaceutical composition comprising a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and / or a GLP-1 / GIP / GCG receptor triple agonist.

[0002] Glucagon-like peptide-1 (GLP-1) is derived from pre-proglucagon, a 158 amino acid precursor polypeptide that is processed in different tissues to form numerous different proglucagon-derived peptides, including glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), and oxyntomodulin (OXM), which are involved in the regulation of food intake as well as various physiological functions, including glucose homeostasis, insulin secretion, gastric emptying, and intestinal growth.

[0003] GLP-1 is produced as a 37-amino acid peptide corresponding to amino acids 72-108 of proglucagon (92-128 of preproglucagon). GLP-1(7-36) amide or GLP-1(7-37) acid are the biologically active forms of GLP-1 that exhibit essentially equivalent activity at the GLP-1 receptor. GLP-1 and GLP-1 analogues that act as agonists at the GLP-1 receptor have been shown to provide effective glycemic control, for example, in patients with type 2 diabetes, and have also been shown to provide weight loss, preservation of beta-cell function, and reduction in hypertension, hypoglycemia, and / or hyperlipidemia.

[0004] Currently, certain GLP-1 analogues are marketed or in development, including Byetta ® & Bydureon BCise ® (exenatide), Ozempic ® (semaglutide), Victoza ® (liraglutide), Adlyxin ® (lixisenatide), Tanzeum ® (albiglutide), and Trulicity ® (dulaglutide).

[0005] Like GLP-1, GIP (Gastric Inhibitory Peptide) not only stimulates insulin secretion in a glucose-dependent manner from beta cells, but also promotes insulin synthesis, induces beta cell proliferation, and has an inhibitory effect on apoptosis [Trumper et al., Mol Endocrinol 15:1559-1570, 2001].

[0006] Currently, GLP-1 / GIP dual agonists are also being developed, for example, Mounjaro ® (tirzepatide) is marketed.

[0007] The GCG receptor regulates the action of glucagon in the liver. Glucagon stimulates gluconeogenesis in the liver, thereby increasing blood sugar levels. Glucagon inhibits glucagon's action via the GCG receptor, thereby maintaining a stable blood sugar level. Currently, development is underway on GLP-1 / GIP / GCG receptor triple agonists.

[0008] Administration of GLP-1 receptor agonists, GLP-1 / GIP receptor agonists, and / or GLP-1 / GIP / GCG receptor triple agonists is mainly administered as an injection due to several barriers such as enzymatic degradation in the gastrointestinal tract and intestinal mucosa, insufficient absorption from the intestinal mucosa, and first pass metabolism in the liver.

[0009] Extended-release injectable formulations of GLP-1 receptor agonists, GLP-1 / GIP receptor agonists, and / or GLP-1 / GIP / GCG receptor triple agonists can provide therapeutic doses of the active ingredient for extended periods in a single injection, eliminating the need for daily injections. Commonly used extended-release injectable formulations include, for example, microspheres and aqueous carriers.

[0010] However, the microspheres lack long-term stability within an aqueous carrier, requiring separate packaging and storage of the microspheres and aqueous carrier. Furthermore, patients experience significant inconvenience due to the multiple steps required to combine the microspheres and aqueous carrier prior to injection.

[0011] [Prior Art Literature]

[0012] [Patent Document]

[0013] (Patent Document 1) Republic of Korea Publication No. 10-2020-0044016

[0014] The present invention has been devised to solve the above problems of the prior art.

[0015] The object of the present invention is to provide a pharmaceutical composition in which microspheres comprising a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and / or a GLP-1 / GIP / GCG receptor triple agonist in a suspension can maintain long-term stability.

[0016] In addition, the purpose is to provide a pharmaceutical composition in which the microspheres stored in a suspension for a long period of time can provide excellent dissolution characteristics.

[0017] In addition, the present invention aims to provide a pharmaceutical composition of microspheres containing a surfactant or polyhydric alcohol as a carrier to increase bioavailability.

[0018] To solve the above problem,

[0019] The present invention relates to microspheres comprising at least one selected from among GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists; and

[0020] A pharmaceutical composition is provided, comprising at least one pharmaceutically acceptable first carrier selected from the group consisting of a fluid oil containing a fatty acid ester, a surfactant, and a polyhydric alcohol.

[0021] In addition, the present invention provides a pharmaceutical composition in which the fluid oil is at least one selected from coconut oil, palm oil, palm kernel oil, sesame oil, soybean oil, almond oil, rapeseed oil, corn oil, sunflower oil, peanut oil, olive oil, castor oil, safflower oil, cottonseed oil, and ethyl oleate.

[0022] In addition, the present invention provides a pharmaceutical composition in which the surfactant is at least one selected from among Poloxamer 188, Poloxamer 407, Polysorbate 20, Polysorbate 60, Polysorbate 80, Polyoxyethylene oleyl ether, Polyoxyethylene cetyl ether, Polyoxyethylene stearyl ether, and Polyoxyethylene lauryl ether.

[0023] In addition, the present invention provides a pharmaceutical composition in which the polyhydric alcohol is at least one selected from ethylene glycol, propylene glycol, polyethylene glycol, glycerol, erythritol, threitol, xylitol, ribitol, mannitol, sorbitol, and maltitol.

[0024] In addition, the present invention provides a pharmaceutical composition wherein the polyhydric alcohol is ethylene glycol, propylene glycol, polyethylene glycol or glycerol.

[0025] In addition, the present invention provides a pharmaceutical composition comprising at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist contained in microspheres in a concentration range of 0.01 mg to 2,000 mg based on 1 mL of the first carrier.

[0026] In addition, the present invention provides a pharmaceutical composition wherein the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist and / or GLP-1 / GIP / GCG receptor triple agonist is at least one selected from exenatide, liraglutide, lacxisenatide, albiglutide, dulaglutide, semaglutide, tirzepatide, cotadutide, taspoglutide, retatrutide and pharmaceutically acceptable salts thereof.

[0027] In addition, the present invention provides a pharmaceutical composition comprising at least one selected from the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist in an amount of 3 to 50% by weight based on the total weight of microparticles.

[0028] In addition, the present invention provides a pharmaceutical composition wherein the microspheres further comprise a biocompatible polymer.

[0029] In addition, the present invention provides a pharmaceutical composition in which the biocompatible polymer is at least one selected from polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, copolymer of lactic acid and caprolactone, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and copolymer of lactic acid and amino acid.

[0030] In addition, the present invention provides a pharmaceutical composition comprising the biocompatible polymer in an amount of 50 to 97 wt% based on the total weight of the microparticles.

[0031] In addition, the present invention provides a pharmaceutical composition further comprising one or more additives selected from a buffer, an isotonic agent, a preservative, and a pH adjusting agent.

[0032] In addition, the present invention provides a pharmaceutical composition comprising the microspheres and at least one selected from the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist and the biocompatible polymer in a weight ratio of 1:1 to 50.

[0033] In addition, the present invention provides a pharmaceutical composition in which the microspheres remain stable for more than 6 months.

[0034] In addition, the present invention provides a pharmaceutical composition which is an injection.

[0035] The pharmaceutical composition of the present invention provides the effect of maintaining long-term stability of microspheres comprising a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and / or a GLP-1 / GIP / GCG receptor triple agonist in a suspension.

[0036] In addition, the above microspheres stored for a long period of time in a suspension provide the effect of exhibiting excellent dissolution characteristics.

[0037] In addition, the surfactant or polyhydric alcohol according to the present invention can increase bioavailability and provide an effect of reducing the administration dose by using microspheres as a carrier.

[0038] Figure 1 is a graph showing the in vivo pharmacokinetics of semaglutide manufactured in Example 6 and Comparative Example 2.

[0039] Hereinafter, the present invention will be described in more detail.

[0040] Unless otherwise defined, all technical terms used in this invention have the same meanings as those commonly understood by those skilled in the art in the relevant field of the present invention. Furthermore, methods or samples similar to or equivalent to those described herein are also included within the scope of the present invention. The contents of all publications cited herein as references are incorporated herein by reference in their entirety.

[0041]

[0042] The present invention relates to microspheres comprising at least one selected from among GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists; and

[0043] A pharmaceutical composition comprising: a first pharmaceutically acceptable carrier selected from the group consisting of a fluid oil containing a fatty acid ester, a surfactant, and a polyhydric alcohol;

[0044] Improving the ease of dosing for GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and / or GLP-1 / GIP / GCG receptor triple agonists is a constant challenge for researchers in this field. To address this challenge, sustained-release microspheres containing these drugs have been developed. These sustained-release microspheres have significantly reduced the number of injections required, significantly improving patient convenience.

[0045] The sustained-release microspheres are suspended in an aqueous carrier and injected into the body as a suspension. However, the low stability of sustained-release microspheres in aqueous carriers has made it difficult to manufacture and distribute them as a suspension formulation. Therefore, the microspheres and aqueous carrier are currently distributed separately, and medical professionals or patients mix them to produce a suspension formulation for injection. Manufacturing such a suspension formulation is not only cumbersome, but also causes problems in accurately adjusting the drug concentration during the manufacturing process when the patient injects the drug directly.

[0046] The pharmaceutical composition of the present invention has the characteristics that the microspheres containing a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and / or a GLP-1 / GIP / GCG receptor triple agonist in a suspension maintain long-term stability, and the microspheres stored for a long period of time exhibit excellent dissolution characteristics.

[0047] In addition, the pharmaceutical composition of the present invention has the characteristics of improving the stability of microspheres, increasing bioavailability, and reducing the administration dose by including at least one selected from a fluid oil containing a fatty acid ester, a surfactant, and a polyhydric alcohol as a first carrier.

[0048] In one embodiment of the present invention, the fluid oil carrier may be a pharmaceutically acceptable carrier having non-aqueous or lipophilic properties. The fluid oil carrier may be substantially inert, so as not to interact with the microspheres, and non-toxic, so as not to adversely affect the patient. Furthermore, the fluid oil carrier may not dissolve the biocompatible polymer forming the microspheres. Furthermore, the fluid oil carrier may not dissolve the drug contained within the microspheres.

[0049] Additionally, microspheres using a fluid oil as a carrier can increase bioavailability compared to microspheres not using the fluid oil as a carrier.

[0050] The term "non-aqueous" above does not exclude the inclusion of trace amounts of residual water that do not adversely affect the solubility of the microspheres. The oil carrier may not dissolve the microspheres to such an extent that the stability of the microspheres is adversely affected or that the initial release control of the microspheres is lost. The oil carrier may also not swell the microspheres to such an extent that the stability of the microspheres is adversely affected.

[0051] The above fluid oil refers to a viscous liquid substance at ambient temperature or slightly higher temperature, and has hydrophobicity (immiscible with water) and lipophilicity (literally miscible with other oils). As the fluid oil carrier, for example, one or more selected from the group consisting of coconut oil, palm oil, palm kernel oil, sesame oil, soybean oil, almond oil, rapeseed oil, corn oil, sunflower oil, peanut oil, olive oil, castor oil, safflower oil, cottonseed oil, and ethyl oleate may be used.

[0052] The above-mentioned fluid oil may be MCT (Medium-Chain Triglycerides) oil. The above-mentioned MCT oil refers to oil manufactured by separating and refining only the medium-chain fatty acids contained in the oil.

[0053] In one embodiment of the present invention, microspheres using a surfactant or polyhydric alcohol as a carrier can increase bioavailability by 10% or more compared to microspheres not using the surfactant or polyhydric alcohol as a carrier.

[0054] In one embodiment of the present invention, the surfactant may be at least one selected from Poloxamer 188, Poloxamer 407, Polysorbate 20, Polysorbate 60, Polysorbate 80, Polyoxyethylene oleyl ether, Polyoxyethylene cetyl ether, Polyoxyethylene stearyl ether, and Polyoxyethylene lauryl ether. More specifically, the surfactant may be, but is not limited to, Poloxamer 188, Poloxamer 407, Polyoxyethylene oleyl ether, Polyoxyethylene cetyl ether, Polyoxyethylene stearyl ether or Polyoxyethylene lauryl ether.

[0055] In one embodiment of the present invention, the polyhydric alcohol may be at least one selected from ethylene glycol, propylene glycol, polyethylene glycol, glycerol, erythritol, threitol, xylitol, ribitol, mannitol, sorbitol, and maltitol. More specifically, the polyhydric alcohol may be ethylene glycol, propylene glycol, polyethylene glycol, and glycerol, but is not limited to these examples.

[0056] In one embodiment of the present invention, the pharmaceutical composition may contain at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist contained in the microspheres in a concentration range of 0.01 mg to 2,000 mg based on 1 mL of the first carrier. Here, the first carrier suspends at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist contained in the microspheres, and the pharmaceutical composition may be suspended by including at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist in an amount of 0.01 mg to 2,000 mg based on 1 mL of the first carrier.

[0057] More specifically, the concentration of the pharmaceutical composition is 0.01 mg or more, 0.05 mg or more, 0.1 mg or more, 0.15 mg or more, 0.2 mg or more, 0.25 mg or more, 0.3 mg or more, 0.35 mg or more, 0.4 mg or more, 0.45 mg or more, 0.5 mg or more, 0.55 mg or more, 0.6 mg or more, 0.65 mg or more, 0.7 mg or more, 0.75 mg or more, 0.8 mg or more, 0.85 mg or more, 0.9 mg or more, 0.95 mg or more, 1.0 mg or more, or 2,000 mg or less, 1,995 mg, of at least one selected from the group consisting of a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and / or a GLP-1 / GIP / GCG receptor triple agonist contained in the microspheres, based on 1 mL of the first carrier. Below, 1,990 mg or less, 1,985 mg or less, 1,980 mg or less, 1,975 mg or less, 1,970 mg or less, 1,965 mg or less, 1,960 mg or less, 1,955 mg or less, 1,950 mg or less, 1,945 mg or less, 1,940 mg or less, 1,935 mg or less, 1,930 mg or less, 1,925 mg or less, 1,920 mg or less, 1,915 mg or less, 1,910 mg or less, 1,905 mg or less, 1,900 mg or less, but is not limited to these ranges.

[0058] The pharmaceutical composition of the present invention may be composed of microspheres and a carrier excluding the microspheres, and the carrier may contain the first carrier in an amount of 20 wt% or more, 30 wt% or more, 40 wt% or more, 50 wt% or more, 60 wt% or more, 70 wt% or more, 80 wt% or more, 90 wt% or more, or a lower limit of 100 wt%, based on 100 wt% of the carrier. In addition, the first carrier may be contained in an amount of 90 wt% or less, 80 wt% or less, 70 wt% or less, 60 wt% or less, 50 wt% or less, 40 wt% or less, or 30 wt% or less. In addition, the first carrier may be contained in a range formed by a combination of the lower limit and the upper limit.

[0059] In the above "pharmaceutical composition comprising microspheres and a carrier excluding microspheres," the carrier refers to a carrier in a broad sense that includes all ingredients used to facilitate administration of the microspheres. For example, additives and the like are also included in the carrier in the broad sense. The carrier may be composed of, for example, the first carrier and an additive.

[0060]

[0061] In one embodiment of the present invention, at least one selected from the GLP-1 receptor agonist, the GIP / GLP-1 receptor agonist, and the GLP-1 / GIP / GCG receptor triple agonist may be selected from the group consisting of exenatide, liraglutide, lacxisenatide, albiglutide, dulaglutide, semaglutide, tirzepatide, cotadutide, taspoglutide, retatrutide, and pharmaceutically acceptable salts thereof, respectively. More specifically, at least one selected from the GLP-1 receptor agonist, the GIP / GLP-1 receptor agonist, and the GLP-1 / GIP / GCG receptor triple agonist may be selected from the group consisting of semaglutide, tirzepatide, retatrutide, and pharmaceutically acceptable salts thereof, respectively.

[0062] The pharmaceutically acceptable salts mentioned above include, without limitation, salts commonly used in this field. The term "pharmaceutically acceptable salt" of the present invention refers to any and all organic or inorganic addition salts of the above compounds, which are relatively non-toxic and harmless to patients and have an effective effect, and in which side effects due to the salt do not reduce the beneficial effects of the active ingredient. Specific examples include, but are not limited to, acetate salts, benzoate salts, hydroxynaphthoate salts, napadiylate salts, and pamoate salts of each of the above drugs, and various forms of salts known in the field may all be included.

[0063] At least one selected from the above GLP-1 receptor agonist, GIP / GLP-1 receptor agonist and GLP-1 / GIP / GCG receptor triple agonist may be manufactured in various forms, for example, may be amorphous or crystalline.

[0064] Microspheres according to one embodiment of the present invention mean microspheres manufactured using a biocompatible polymer in which the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, or GLP-1 / GIP / GCG receptor triple agonist is encapsulated, and in the present specification, these are simply referred to as microspheres containing a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, or a GLP-1 / GIP / GCG receptor triple agonist, a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, or a GLP-1 / GIP / GCG receptor triple agonist microsphere, or a microsphere.

[0065] In one embodiment of the present invention, a biocompatible polymer means a polymer that is guaranteed to be safe in vivo and does not cause high cytotoxicity or inflammatory response when administered into a living body, and is also referred to simply as a polymer in this specification.

[0066] In one embodiment of the present invention, the microspheres may further include a biocompatible polymer. As the biocompatible polymer, any biocompatible polymer known in the art may be used without limitation, and specifically, for example, at least one selected from among polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, copolymers of lactic acid and caprolactone, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acids, and copolymers of lactic acid and amino acids may be used.

[0067] In one embodiment of the present invention, the biocompatible polymer may be one having an intrinsic viscosity of 0.15 dL / g to 1.7 dL / g, 0.15 dL / g to 1.3 dL / g, or 0.15 dL / g to 1.2 dL / g.

[0068] The above intrinsic viscosity refers to that measured at a concentration of 0.05 to 3% (w / v) in chloroform at 25°C using an Ubbelohde viscometer. When the above intrinsic viscosity is less than 0.15 dL / g, the molecular weight of the polymer is insufficient, making it difficult to exhibit a sustained-release effect of the drug. When the intrinsic viscosity exceeds 1.7 dL / g, the drug release may be excessively delayed. In addition, when manufacturing microspheres using a polymer with a high intrinsic viscosity, there is a problem that an excessive amount of manufacturing solvent must be used due to the high viscosity of the polymer, and it is difficult to manufacture reproducible microspheres.

[0069] Examples of commercially available polymers having the above properties include Evonik's Resomer series RG502H, RG503H, RG504H, RG502, RG503, RG504, RG653H, RG752H, RG752S, RG755S, RG750S, RG757S, RG858S, R202H, R203H, R205H, R202S, R203S, R205S, R206S, and R207S, Corbion's PDL 02A, PDL 02, PDL 04, PDL 05, PDLG 7502A, PDLG 7502, PDLG 7507, PDLG 5002A, PDLG 5002, PDLG 5004A, and Examples include PDLG 5004.

[0070] In one embodiment of the present invention, the microspheres may further include one or more release-controlling agents selected from butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, heptadecylic acid, stearic acid, nonadecylic acid, arachidic acid, isocrotonic acid, oleic acid, elaidic acid, sorbic acid, linoleic acid, arachidonic acid, hydroxynaphthoic acid, napadiylic acid, and pamoic acid.

[0071] In one embodiment of the present invention, at least one selected from the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist may be included in an amount of 3 to 50 wt% based on the total weight of the microparticles. More specifically, at least one selected from the GLP-1 receptor agonist, the GIP / GLP-1 receptor agonist and the GLP-1 / GIP / GCG receptor triple agonist is present in an amount of 3.0 wt% or more, 3.5 wt% or more, 4.0 wt% or more, 4.5 wt% or more, 5.0 wt% or more, 5.5 wt% or more, 6.0 wt% or more, 6.5 wt% or more, 7.0 wt% or more, 7.5 wt% or more, 8.0 wt% or more, 8.5 wt% or more, 9.0 wt% or more, 9.5 wt% or more, 10.0 wt% or more, or 50 wt% or less, 49.5 wt% or less, 49.0 wt% or less, 48.5 wt% or less, 48.0 wt% or less, 47.5 wt% or less, 47.0 wt% or less, 46.5 wt% or less, based on the total weight of the microspheres. Below, 46.0 wt% or less, 45.5 wt% or less, 45.0 wt% or less, 44.5 wt% or less, 44.0 wt% or less, 43.5 wt% or less, 43.0 wt% or less, 42.5 wt% or less, 42.0 wt% or less, 41.5 wt% or less, 41.0 wt% or less, 40.5 wt% or less, 40.0 wt% or less.

[0072] If at least one selected from the above GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist is included in an amount of less than 3 wt%, it is not preferable because a single administration cannot provide long-term efficacy. In addition, if at least one selected from the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist is included in an amount of more than 50 wt%, the initial release amount of the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, or GLP-1 / GIP / GCG receptor triple agonist in the body environment may be excessively high, which may cause a problem in that the blood concentration of the drug rapidly increases.

[0073] In addition, the content range of the biocompatible polymer included in the microspheres may be 50 to 97 wt% based on the total weight of the microspheres. More specifically, the content of the biocompatible polymer may be 50 wt% or more, 55 wt% or more, 60 wt% or more, or 97 wt% or less, 96.0 wt% or less, 95.0 wt% or less, 94.0 wt% or less, 93.0 wt% or less, 92.0 wt% or less, 91.0 wt% or less, or 90.0 wt% or less based on the total weight of the microspheres, but is not limited to these ranges.

[0074] In the above, if the biocompatible polymer exceeds 97 wt%, the dissolution of the drug may be too slow to secure a consistent blood drug profile, and if the biocompatible polymer is included in an amount of less than 50 wt% based on the total weight of the microspheres, the distribution of the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, or GLP-1 / GIP / GCG receptor triple agonist may relatively increase, resulting in an initial excessive release or inability to maintain the drug effect for a desired period of time.

[0075] In one embodiment of the present invention, the microspheres are mixed with at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist, and the biocompatible polymer, for example, at a ratio of 1:1 to 50, 1:1.5 to 50, 1:1.6 to 50, 1:1.7 to 50, 1:1 to 47, 1:1.5 to 47, 1:1.6 to 47, 1:1.7 to 47, 1:1 to 45, 1:1.5 to 45, 1:1.6 to 45, 1:1.7 to 45, 1:1 to 42, 1:1.5 to 42, 1:1.6 to 42, 1:1.7 to 42, 1:1 to 40, 1:1.5 to 40, 1:1.6 to 40, It may be included in a weight ratio of 1:1.7~40, 1:1~38, 1:1.5~38, 1:1.6~38, 1:1.7~38, 1:1~35, 1:1.5~35, 1:1.6~35, or 1: 1.7~35.

[0076] At this time, if the weight ratio of the biocompatible polymer to at least one selected from the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist is less than 1.0, it is not preferable because fatal side effects may occur due to the initial drug over-release phenomenon, and if the weight ratio exceeds 50, the drug dissolution may be too slow, making it difficult to secure a constant blood drug profile.

[0077] In one embodiment of the present invention, the microspheres may have a dissolution rate of at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist of 60 wt% or less, 55 wt% or less, or 50 wt% or less within 7 days.

[0078] Additionally, the microspheres may have a dissolution rate of at least one selected from among a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist of 25 wt% or less, 23 wt% or less, or 20 wt% or less within 3 days.

[0079] In particular, the microspheres of the present invention may have a drug release rate of at least one drug selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist of 10 wt% or less, 8 wt% or less, or 5 wt% or less during the first day of administration.

[0080] In addition, the microspheres of the present invention may continuously release the drug for 10 days or more, 20 days or more, 1 month or more, 2 months or more, 3 months or more, 4 months or more, 5 months or more, or 6 months or more.

[0081] In one embodiment of the present invention, the microspheres can be manufactured by various microsphere manufacturing methods known in the art (e.g., O / W type, O / O type or W / O / W type solvent evaporation method or solvent extraction method, microsphere manufacturing method by spray drying, microsphere manufacturing method by phase separation, etc.).

[0082] In one embodiment of the present invention, the microspheres may be prepared by a solvent evaporation or extraction method using an emulsion, more preferably, an O / W (oil-in-water) type emulsion comprising a biocompatible polymer; at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist; and a dispersing solvent; and agglomerating the emulsion into microspheres.

[0083] In order to manufacture microspheres by manufacturing the above O / W type emulsion and coagulating it into polymer microparticles, first, an O / W type emulsion including a biocompatible polymer; at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist; and a dispersion solvent is manufactured.

[0084] The above O / W type emulsion can be manufactured using a conventional method known in the art, and more specifically, it can be manufactured by adding a dispersion phase including at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist and a biocompatible polymer to a dispersion solvent.

[0085] Microspheres containing at least one selected from the group consisting of GLP-1 receptor agonists, GIP / GLP-1 receptor agonists and GLP-1 / GIP / GCG receptor triple agonists can be prepared by coagulating an emulsion into microspheres by solvent extraction and / or solvent evaporation, or by coagulation by ammonolysis with the addition of ammonia or hydrolysis with the addition of an acid or a base. A water-insoluble organic solvent that is converted into a water-soluble solvent by the ammonolysis or hydrolysis reaction can be additionally included during the preparation of the emulsion.

[0086] In the case of the above solvent evaporation method, the method is not limited thereto, but for example, the method described in U.S. Patent Nos. 5,271,945, 5,985,309 and 6,471,996, etc., i.e., dissolving a polymer compound in an organic solvent, dispersing or dissolving a drug in the organic solvent, emulsifying in a dispersion medium such as water to prepare an O / W type emulsion, and then diffusing the organic solvent in the emulsion into the dispersion medium and evaporating through the air / water interface, thereby forming polymer microspheres containing at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and a GLP-1 / GIP / GCG receptor triple agonist.

[0087] The above solvent extraction method includes a conventional solvent extraction method used for producing microspheres containing at least one selected from among GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists, such as effectively extracting the organic solvent in the emulsion droplets using a large amount of solubilizing solvent.

[0088] As a method of simultaneously applying the solvent evaporation method and the solvent extraction method, for example, the methods described in U.S. Patent Nos. 4,389,840, 4,530,840, 6,368,632, 6,544,559, and 6,572,894 can be applied.

[0089] The coagulation by the above ammonolysis process refers to a method of coagulating fine particles by adding ammonia to an O / W type emulsion containing a water-insoluble organic solvent to induce ammonolysis, converting the water-insoluble organic solvent into a water-soluble solvent, for example, as described in Korean Patent No. 918092.

[0090] The coagulation by the above hydrolysis process is a method of coagulating fine particles by adding a base such as NaOH, LiOH, or KOH, or an acid solution such as HCl or H2SO4 to an O / W type emulsion containing a water-insoluble organic solvent, thereby inducing hydrolysis, which is a type of hydrolysis reaction of an ester, and converting the water-insoluble organic solvent into a water-soluble solvent, as described in, for example, Korean Patent Application Nos. 2009-109809 and 2010-70407.

[0091] In one embodiment of the present invention, the microspheres may be W1 / O / W2 (water-in-oil-in-water) microspheres prepared by preparing a W1 / O (water-in-oil) type emulsion including an inner phase (W1) in which at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist is dispersed or dissolved in an aqueous solvent; and an oil phase (O) in which a biocompatible polymer is dissolved in a non-aqueous solvent; and dispersing the same in an outer phase (W2). In this case, the microspheres may be prepared by a double emulsification evaporation method.

[0092] In order to manufacture microspheres by preparing the above W / O / W type emulsion and coagulating it into polymer microparticles, first, a W / O / W type emulsion containing at least one selected from a biocompatible polymer, a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist, and a dispersion solvent is prepared.

[0093] At this time, the W / O / W type emulsion can be manufactured using a conventional method known in the art, and more specifically, it can be manufactured by adding a dispersion phase including at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist and a biocompatible polymer to a dispersion solvent.

[0094] Microspheres containing at least one selected from the group consisting of GLP-1 receptor agonists, GIP / GLP-1 receptor agonists and GLP-1 / GIP / GCG receptor triple agonists can be prepared by coagulating an emulsion into microspheres by solvent extraction and / or solvent evaporation, or by coagulation by ammonolysis with the addition of ammonia or hydrolysis with the addition of an acid or a base. A water-insoluble organic solvent that is converted into a water-soluble solvent by the ammonolysis or hydrolysis reaction can be additionally included during the preparation of the emulsion.

[0095] The above solvent evaporation method, solvent extraction method, coagulation by ammonolysis process, and coagulation by hydrolysis process can be performed in the same manner as described above.

[0096] In one embodiment of the present invention, the pharmaceutical composition may further comprise one or more pharmaceutically acceptable additives. The additives may be, for example, one or more selected from the group consisting of buffers, isotonic agents, preservatives, and pH regulators.

[0097] The above additive is distinct from the first carrier, and the pharmaceutical composition according to the present invention can be formulated in a suitable form comprising the microspheres, a pharmaceutically acceptable first carrier, and the additive.

[0098] Examples of buffers that can be used include, but are not limited to, phosphate buffer, TRIS, citrate, etc., and any buffer known in the art can be used without limitation. The phosphate buffer may include sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, etc. The buffer may be included in the pharmaceutical composition at a concentration of, for example, 0.01 to 50 mM.

[0099] Examples of the isotonic agent that can be used include, but are not limited to, propylene glycol, sodium chloride, mannitol, sucrose, sorbitol, trehalose, lactose, etc., and isotonic agents known in the art can be used without limitation. The isotonic agent can be included in the pharmaceutical composition at a concentration of, for example, 8 mg / ml to 50 mg / ml, or 8 mg / ml to 30 mg / ml.

[0100] Examples of the preservatives that can be used include, but are not limited to, phenol, and any preservative known in the art can be used without limitation. The preservative may be included in an amount of, for example, 1 wt% or less, 0.5 wt% or less, or 0.1 wt% or less based on the total weight of the pharmaceutical composition.

[0101] Examples of pH adjusters that can be used include, but are not limited to, HCl, NaOH, or acetate, and any pH adjuster known in the art can be used without limitation.

[0102] The pharmaceutical composition of the present invention can be formulated into various forms, for example, as a parenteral administration preparation. Such parenteral administration preparations may include, but are not limited to, injections, creams, lotions, topical ointments, oils, moisturizers, gels, aerosols, patches, and nasal inhalers.

[0103] The above parenteral dosage form may further include, in addition to the microparticles, a thickening agent, a stabilizer, an isotonic agent, a pH regulator, a surfactant, an excipient and / or a carrier.

[0104] The above usable isotonic agents include water-soluble excipients or sugars such as mannitol, sucrose, sorbitol, trehalose, lactose, and sodium chloride.

[0105] Examples of the thickener include sodium carmellose, sodium carboxymethyl cellulose, and povidone.

[0106] Examples of the above surfactants include polyvinyl alcohol, etc. In addition, examples of buffering agents include sodium dihydrogen phosphate, anhydrous citric acid, sodium hydroxide, sodium chloride, etc.

[0107] The above parenteral administration formulation is not limited to the forms exemplified above and may be formulated in a manner known in the art.

[0108] In one embodiment of the present invention, the pharmaceutical composition may be an injection.

[0109] In one embodiment of the present invention, the pharmaceutical composition may be an injectable agent for subcutaneous or intramuscular injection.

[0110] In one embodiment of the present invention, the pharmaceutical composition may be administered to a subject at intervals of one month to one year.

[0111] In one embodiment of the present invention, the pharmaceutical composition can be used to prevent or treat diabetes, beta-cell function preservation, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or degenerative neurological diseases such as Alzheimer's disease and Parkinson's disease.

[0112] The pharmaceutical composition of the present invention can be administered in a therapeutically effective amount of a GLP 1 receptor agonist, a GIP / GLP-1 receptor agonist, or a GLP-1 / GIP / GCG receptor triple agonist, for example, an effective amount for treating diabetes, specifically type 2 diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The therapeutically effective amount of a GLP 1 receptor agonist, a GIP / GLP-1 receptor agonist, or a GLP-1 / GIP / GCG receptor triple agonist can be assessed by a physician.

[0113] The pharmaceutical composition of the present invention may be administered once every two weeks, once every three weeks, once every month, once every three months, once every six months, or once every year, but is not limited thereto.

[0114] The pharmaceutical composition of the present invention may be administered, for example, by subcutaneous injection. The subcutaneous injection may be performed, for example, using a pre-filled syringe, such as a pen-syringe. The pen-syringe may be a disposable syringe containing a single dose, or a metered dose syringe (syringe with a dose metering device) that injects only the single dose amount at a time.

[0115] The pharmaceutical composition of the present invention exhibits sufficient efficacy as at least one of a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist during the treatment period, and can be usefully used for the prevention or treatment of diabetes, specifically type 2 diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or degenerative neurological diseases such as Alzheimer's disease and Parkinson's disease.

[0116] The pharmaceutical composition of the present invention can be manufactured, transported and stored in a state in which microspheres containing at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and a GLP-1 / GIP / GCG receptor triple agonist are suspended in a fluid oil carrier containing a fatty acid ester.

[0117] In addition, the pharmaceutical composition of the present invention can be manufactured, transported and stored in a state in which microspheres containing at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and a GLP-1 / GIP / GCG receptor triple agonist are suspended in a carrier containing a surfactant or a polyhydric alcohol.

[0118] In addition, the pharmaceutical composition of the present invention can be manufactured, transported and stored in a state in which microspheres containing at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist and a GLP-1 / GIP / GCG receptor triple agonist are suspended in a carrier containing a fluid oil containing a fatty acid ester and a surfactant or a polyhydric alcohol.

[0119] The pharmaceutical composition of the present invention may be provided in a sealed container. The sealed container may be, for example, a vial (disposable or multi-use), a syringe, an injection pen (e.g., disposable or multi-use), etc.

[0120] The pharmaceutical composition of the present invention provides long-term storage stability. For example, the pharmaceutical composition of the present invention can be stored in a stable state for at least 6 months, at least 1 year, at least 1 year and 6 months, or at least 2 years. The term "stable state" refers to a state in which the drug activity can be maintained at least 90%, 95%, or 99% of the activity in the initial formulation (i.e., 100%). In particular, it refers to the maintenance of the particle size and / or shape of the microspheres, thereby maintaining the drug activity within the above range.

[0121] The microspheres included in the pharmaceutical composition of the present invention can be prepared using a method known in the art, for example, a “solvent extraction and evaporation method.”

[0122] Specifically, it can be manufactured by a method comprising the following steps:

[0123] (a) a step of preparing a solution (dispersed phase) containing at least one selected from among a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist and a polymer by dissolving a biocompatible polymer in an organic solvent;

[0124] (b) a step of preparing an emulsion by adding at least one selected from the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist prepared in the above step (a) and a polymer-containing solution to an aqueous solution phase (continuous phase);

[0125] (c) a step of forming microspheres by continuously extracting and evaporating an organic solvent from the dispersed phase of the emulsion state prepared in step (b); and

[0126] (d) A step of recovering microspheres from the continuous phase of step (c) and preparing microspheres containing at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist.

[0127] In the above manufacturing method, one or more selected from among GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists, and biocompatible polymers, etc. have been described above, so description thereof is omitted in this section.

[0128] In the above step (a), at least one selected from among a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist may be first dissolved in an organic solvent and then mixed with a biocompatible polymer solution.

[0129] In the above step (a), an organic solvent that is miscible with water or an organic solvent that is not miscible with water may be used. Alternatively, a mixed solvent of an organic solvent that is miscible with water and an organic solvent that is not miscible with water may be used.

[0130] It is preferable to use the organic solvent having a property of being immiscible with water in an amount of 50% (v / v) or more of the total solvent. When utilizing the property of being immiscible with water of the organic solvent, an emulsion can be efficiently formed by homogeneously mixing the dispersed phase in the continuous phase.

[0131] The type of organic solvent that dissolves at least one selected from the above GLP-1 receptor agonist, GIP / GLP-1 receptor agonist and GLP-1 / GIP / GCG receptor triple agonist and the biocompatible polymer is not particularly limited, but preferably, one or two or more mixed solvents selected from the group consisting of dichloromethane, chloroform, ethyl acetate, methyl ethyl ketone, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, N-methylpyrrolidone, acetic acid, methyl alcohol, ethyl alcohol, propyl alcohol and benzyl alcohol can be used.

[0132] In the step (b) above, the step of preparing an emulsion by adding at least one selected from among a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist and a polymer-containing solution (dispersed phase) to an aqueous solution phase (continuous phase) can be performed using a homogenizer such as a high-speed stirrer, an inline mixer, a membrane emulsion method, a microfluidics emulsion method, an ultrasonic mixer, or a static mixer.

[0133] In the step (b), the continuous phase may further include a surfactant. The type of the surfactant is not particularly limited, and any surfactant that can help the polymer solution form a stable droplet dispersion phase in the continuous phase, as well as at least one selected from among GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists, may be used. As the surfactant, a hydrophilic polymer selected from the group consisting of methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, and mixtures thereof may be used, and polyvinyl alcohol is particularly preferably used.

[0134] The surfactant may be added to the continuous phase at a concentration of 0.1 to 3% (w / v), more preferably 0.3 to 2% (w / v). If the concentration of the surfactant is less than 0.1%, a dispersed phase or emulsion in the form of droplets may not be formed within the continuous phase, and if the concentration of the surfactant exceeds 3%, it may be difficult to remove the surfactant after the microspheres are formed.

[0135] Water can be used as the aqueous solution (continuous phase) of the above step (b), and the pH of the aqueous solution can be 4.0 to 10, but is not limited thereto. NaCl, which acts as an osmotic regulator, can be used to control the initial release.

[0136] In step (c), if the emulsion is maintained or stirred at a temperature below the boiling point of the organic solvent for a certain period of time, for example, 2 to 48 hours, the organic solvent can be extracted from the dispersed phase into the continuous phase. A portion of the organic solvent extracted into the continuous phase can evaporate from the surface. At this time, the dispersed phase in the form of droplets can solidify to form microspheres.

[0137] In order to efficiently remove the organic solvent in step (c) above, the continuous phase may be heated for a certain period of time. The heating temperature is not limited and can be appropriately adjusted by a person skilled in the art depending on the organic solvent used.

[0138] The method of recovering the microspheres in the above step (d) can be performed using various known techniques, for example, methods such as filtration or centrifugation can be used.

[0139] Between steps (c) and (d), it is also possible to remove any remaining surfactant through filtration and washing, and then filter again to recover the microspheres. The washing step to remove the remaining surfactant can typically be performed using water, and the washing step can be repeated several times.

[0140] The microspheres obtained after the above step (d) can be dried using a conventional drying method to obtain the final dried microspheres.

[0141] The microspheres of the present invention can also be manufactured by the following method.

[0142] (1) A step of preparing an inner phase (W1) by dissolving or dispersing at least one selected from a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist in a solvent;

[0143] (2) A step of preparing an oil phase (O) by dissolving a biocompatible polymer in one or more solvents;

[0144] (3) A step of dispersing an internal phase (W1) in the oil phase (O) to prepare a water-in-oil (W1 / O) type emulsion;

[0145] (4) A step of forming microspheres by dispersing the water-in-oil (W1 / O) type emulsion into an external continuous phase (W2) to produce a water-in-oil (W1 / O / W2) type emulsion; and

[0146] (5) A method for manufacturing microparticles is provided, including a step of removing the solvent.

[0147] The method for manufacturing microspheres of the present invention may be applied to all of the microspheres and methods for manufacturing microspheres described above that are compatible with the manufacturing method (type of biocompatible polymer, intrinsic viscosity thereof, etc.). Therefore, any overlapping information will be omitted below.

[0148] The above step (1) may be a step of preparing a water phase (W1) by dissolving, for example, at least one selected from among a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist in distilled water.

[0149] In the above step (2), the type of solvent is not particularly limited, and for example, dimethyl sulfoxide, dichloromethane, or a mixed solvent thereof may be used. In particular, dichloromethane may be preferably used.

[0150] The above step (3) is a step of preparing a water-in-oil (W1 / O) type emulsion by dispersing the inner phase (W1) prepared in step (1) into the oil phase (O) prepared in step (2).

[0151] In the above step (3), the weight ratio of the oil phase (O) to the internal phase (W1) may be 1:10 or less.

[0152] The above step (4) is a step of solidifying microspheres by dispersing the water-in-oil (W1 / O) type dispersed phase prepared in the above step (3) in the external continuous phase (W2) to prepare a water-in-oil-in-water (W1 / O / W2) type emulsion solution.

[0153] In the above step (4), the external continuous phase (W2) may include a hydrophilic polymer as a surfactant, and the type thereof is not particularly limited, and any one selected from among GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists and a dispersed phase including a biocompatible polymer may be used as long as it can help form a dispersed phase of stable droplets within the external continuous phase.

[0154] In the above step (4), the external continuous phase may be a hydrophilic polymer aqueous solution of 0.1 to 6% (w / v), preferably 0.1 to 4% (w / v).

[0155] In the above step (4), a dispersed phase (W1 / O) containing at least one selected from among the GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists prepared in the above step (3) and a biocompatible polymer is added to the external continuous phase containing the hydrophilic polymer by drop-by-drop or by using an in-line mixer, and stirred vigorously to prepare a water-in-oil-in-water (W1 / O / W2) type emulsion solution.

[0156] Afterwards, in step (5), the solvent is removed, and the desired microspheres can be obtained after conventional filtration and washing. That is, a step of washing the obtained microspheres using an organic solvent such as ethanol may be included to enhance the initial release inhibition effect, if necessary.

[0157] Hereinafter, the present invention will be described in detail using examples. However, the examples according to the present invention may be modified in various ways, and the scope of the present invention should not be construed as being limited to the examples described below. These examples are provided to more fully explain the present invention to those of ordinary skill in the art.

[0158]

[0159] Manufacturing Example 1: Manufacturing of semaglutide microspheres

[0160] <Continuous phase manufacturing>

[0161] 900 ml of distilled water was added to the reactor, and 4.5 g of polyvinyl alcohol (PVA) and 4.5 g of sodium chloride (NaCl) were weighed and added. A 0.5% (w / v) polyvinyl alcohol aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0162] <Preparation of Semaglutide Solution>

[0163] 0.32 g of semaglutide and 2.4 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve. The prepared solution was stored in the refrigerator.

[0164] <PLGA 용액의 제조>

[0165] 2.88 g of PLGA (inherent viscosity 0.15 dL / g to 1.7 dL) was dissolved in 9.6 ml of dichloromethane by stirring at 300 rpm.

[0166] Emulsification

[0167] The PLGA solution prepared above was taken with a syringe, added to the semaglutide solution, and stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0168] <Recovery of microspheres>

[0169] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer (Kinematica) for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0170] Manufacturing Example 2: Manufacturing of semaglutide microspheres

[0171] <Continuous phase manufacturing>

[0172] 900 ml of distilled water was added to the reactor, and 4.5 g of polyvinyl alcohol (PVA) and 4.5 g of sodium chloride (NaCl) were weighed and added. A 0.5% (w / v) polyvinyl alcohol aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0173] <Preparation of Semaglutide Solution>

[0174] 0.48 g of semaglutide and 2.4 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0175] <PLGA 용액의 제조>

[0176] 1.44 g of PLGA (inherent viscosity 0.15 dL / g to 1.7 dL / g) was dissolved in 4.8 ml of dichloromethane by stirring at 300 rpm.

[0177] Emulsification

[0178] The PLGA solution prepared above was taken with a syringe, added to the semaglutide solution, and stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0179] <Recovery of microspheres>

[0180] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer (Kinematica) for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0181]

[0182] Example 1: Preparation of a liquid formulation injection containing semaglutide microspheres and MCT oil

[0183] Semaglutide microspheres of Manufacturing Example 1 corresponding to 3 mg / kg of semaglutide were weighed and placed in a vial, and then MCT oil was added and suspended to prepare a semaglutide microsphere injection.

[0184] Example 2: Preparation of a liquid formulation injection containing semaglutide microspheres and castor oil

[0185] Semaglutide microsphere injection was prepared in the same manner as in Example 1, except that MCT oil was replaced with Castor oil.

[0186] Example 3: Preparation of a liquid formulation injection containing semaglutide microspheres and cottonseed oil

[0187] Semaglutide microsphere injection was prepared in the same manner as in Example 1, except that MCT oil was replaced with cottonseed oil.

[0188] Example 4: Preparation of a liquid formulation injection containing semaglutide microspheres and sesame oil

[0189] Semaglutide microsphere injection was prepared in the same manner as in Example 1, except that MCT oil was replaced with sesame oil.

[0190] Example 5: Preparation of a liquid formulation injection containing semaglutide microspheres and Polyoxyl 35 castor oil

[0191] Semaglutide microsphere injection was prepared in the same manner as in Example 1, except that MCT oil was replaced with Polyoxyl 35 castor oil.

[0192] Example 6: Preparation of a liquid formulation injection comprising semaglutide microspheres and propylene glycol liquid carrier

[0193] The microspheres manufactured in the above Manufacturing Example 2 were weighed so that the dosage of semaglutide would be 1 mg / kg, and then propylene glycol was added as a carrier, and these were mixed to manufacture a semaglutide microsphere injection.

[0194] Example 7: Preparation of a liquid formulation injection containing semaglutide microspheres and MCT oil

[0195] Semaglutide microsphere injection was prepared in the same manner as in Example 6, except that propylene glycol was replaced with MCT oil.

[0196] Comparative Example 1: Preparation of a liquid formulation injection containing semaglutide microspheres and a diluent.

[0197] A semaglutide microsphere injection was prepared in the same manner as in Example 1, except that MCT oil was replaced with a diluent containing citric acid anhydrous, sodium phosphate monohydrate, sodium carboxymethylcellulose, polysorbate 20, sodium chloride, and sodium hydroxide.

[0198] Comparative Example 2: Preparation of a liquid formulation injection containing semaglutide microspheres and a diluent.

[0199] A semaglutide microsphere injection was prepared in the same manner as in Example 6, except that propylene glycol was replaced with a diluent containing anhydrous citric acid, sodium phosphate monohydrate, sodium carboxymethylcellulose, polysorbate 20, sodium chloride, and sodium hydroxide.

[0200]

[0201] Manufacturing Example 3: Manufacturing of tirzepatide microspheres

[0202] <Continuous phase manufacturing>

[0203] 900 ml of distilled water was added to the reactor, and 4.5 g of polyvinyl alcohol (PVA) and 4.5 g of sodium chloride (NaCl) were weighed and added. A 0.5% (w / v) polyvinyl alcohol aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0204] <Preparation of Tirzepatide Solution>

[0205] 0.3 g of tirzepatide and 1.0 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0206] <PLGA 용액의 제조>

[0207] 1.2 g of PLGA (inherent viscosity 0.15 dL / g to 1.7 dL / g) was dissolved in 3 ml of dichloromethane by stirring at 300 rpm. The prepared solution was stored in the refrigerator.

[0208] Emulsification

[0209] The PLGA solution prepared above was taken with a syringe, added to the tirzepatide solution, and stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0210] Manufacturing Example 4: Manufacturing of tirzepatide microspheres

[0211] <Continuous phase manufacturing>

[0212] 900 ml of distilled water was added to the reactor, and 4.5 g of polyvinyl alcohol (PVA) and 4.5 g of sodium chloride (NaCl) were weighed and added. A 0.5% (w / v) polyvinyl alcohol (PVA) aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0213] <Preparation of Tirzepatide Solution>

[0214] 0.386 g of tirzepatide and 1.5 ml of distilled water were weighed and added to a 20 ml vial, stirred at 150 rpm to dissolve, and then 0.037 ml of propylene glycol was added and stirred to dissolve.

[0215] <PLGA 용액의 제조>

[0216] 0.9 g of PLGA (inherent viscosity 0.15 dL / g to 1.7 dL / g) was dissolved in 3 ml of dichloromethane by stirring at 300 rpm.

[0217] Emulsification

[0218] The PLGA solution prepared above was taken with a syringe, added to the tirzepatide solution, and stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0219] <Recovery of microspheres>

[0220] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer (Kinematica) for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0221] Example 8: Preparation of a liquid formulation injection containing tirzepatide microspheres and MCT oil

[0222] The tirzepatide microspheres of Manufacturing Example 3 corresponding to 3 mg / kg of tirzepatide were weighed and placed in a vial, and then MCT oil was added and suspended to prepare a tirzepatide microsphere injection.

[0223] Example 9: Preparation of a liquid formulation injection containing tirzepatide microspheres and castor oil

[0224] A tirzepatide microsphere injection was prepared in the same manner as in Example 8, except that MCT oil was replaced with Castor oil.

[0225] Example 10: Preparation of a liquid formulation injection containing tirzepatide microspheres and cottonseed oil

[0226] A tirzepatide microsphere injection was prepared in the same manner as in Example 8, except that MCT oil was replaced with cottonseed oil.

[0227] Example 11: Preparation of a liquid formulation injection containing tirzepatide microspheres and sesame oil

[0228] A tirzepatide microsphere injection was prepared in the same manner as in Example 8, except that MCT oil was replaced with sesame oil.

[0229] Example 12: Preparation of a liquid injection formulation containing tirzepatide microspheres and Polyoxyl 35 castor oil

[0230] A tirzepatide microsphere injection was prepared in the same manner as in Example 8, except that MCT oil was replaced with Polyoxyl 35 castor oil.

[0231] Example 13 Preparation of a liquid formulation injection comprising tirzepatide microparticles and propylene glycol liquid carrier

[0232] The microspheres manufactured in the above Manufacturing Example 4 were weighed so that the dosage of tirzepatide would be 1 mg / kg, and then propylene glycol was added as a carrier, and these were mixed to manufacture a tirzepatide microsphere injection.

[0233] Comparative Example 3: Preparation of a liquid formulation injection containing tirzepatide microspheres and a diluent.

[0234] A tirzepatide microsphere injection was prepared in the same manner as in Example 8, except that MCT oil was replaced with a diluent including citric acid anhydrous, sodium phosphate monohydrate dihydrate, sodium carboxymethylcellulose, polysorbate 20, sodium chloride, and sodium hydroxide.

[0235] Comparative Example 4: Preparation of liquid injection formulation of tirzepatide microspheres

[0236] A tirzepatide microsphere injection was prepared in the same manner as in Example 13, except that propylene glycol was replaced with a diluent including citric acid anhydride, sodium phosphate monohydrate dihydrate, sodium carboxymethylcellulose, polysorbate 20, sodium chloride, and sodium hydroxide.

[0237]

[0238] Experimental Example 1: In vivo pharmacokinetics test using beagles

[0239] The above semaglutide microparticle formulation injection (Comparative Example 2) and the injection containing semaglutide microparticles and propylene glycol (Example 6) were administered to beagles, and then the blood semaglutide concentration was measured.

[0240] Specifically, each sample was injected subcutaneously into a beagle using a 23-gauge syringe. Blood samples were collected at designated times, and the blood concentration of semaglutide was measured using LC-MS / MS. The changes in the blood concentration of semaglutide are shown in Figure 1.

[0241] Experimental Example 2: In vivo pharmacokinetics test using beagles

[0242] The above tirzepatide microparticle injection (Comparative Example 4) and the injection containing tirzepatide microparticles and propylene glycol (Example 13) were administered to beagles, and then the blood semaglutide concentration was measured.

[0243] Specifically, each sample was injected subcutaneously into a beagle using a 23-gauge syringe, blood was collected at designated times, and the blood concentration of semaglutide was measured using LC-MS / MS.

Claims

1. Microspheres comprising at least one selected from among GLP-1 receptor agonists, GIP / GLP-1 receptor agonists, and GLP-1 / GIP / GCG receptor triple agonists; and A pharmaceutical composition comprising at least one pharmaceutically acceptable first carrier selected from the group consisting of a fluid oil containing a fatty acid ester, a surfactant, and a polyhydric alcohol.

2. In paragraph 1, A pharmaceutical composition wherein the fluid oil is at least one selected from coconut oil, palm oil, palm kernel oil, sesame oil, soybean oil, almond oil, rapeseed oil, corn oil, sunflower oil, peanut oil, olive oil, castor oil, safflower oil, cottonseed oil, and ethyl oleate.

3. In paragraph 1, A pharmaceutical composition, wherein the surfactant is at least one selected from among Poloxamer 188, Poloxamer 407, Polysorbate 20, Polysorbate 60, Polysorbate 80, Polyoxyethylene oleyl ether, Polyoxyethylene cetyl ether, Polyoxyethylene stearyl ether, and Polyoxyethylene lauryl ether.

4. In paragraph 1, A pharmaceutical composition, wherein the polyhydric alcohol is at least one selected from ethylene glycol, propylene glycol, polyethylene glycol, glycerol, erythritol, threitol, xylitol, ribitol, mannitol, sorbitol, and maltitol.

5. In paragraph 4, A pharmaceutical composition wherein the polyhydric alcohol is ethylene glycol, propylene glycol, polyethylene glycol or glycerol.

6. In paragraph 1, The pharmaceutical composition comprises at least one selected from among a GLP-1 receptor agonist, a GIP / GLP-1 receptor agonist, and a GLP-1 / GIP / GCG receptor triple agonist contained in microspheres, in a concentration range of 0.01 mg to 2,000 mg, based on 1 mL of the first carrier.

7. In paragraph 1, A pharmaceutical composition, wherein the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist and / or GLP-1 / GIP / GCG receptor triple agonist is at least one selected from exenatide, liraglutide, lacxisenatide, albiglutide, dulaglutide, semaglutide, tirzepatide, cotadutide, taspoglutide, retatrutide and pharmaceutically acceptable salts thereof.

8. In paragraph 1, A pharmaceutical composition, wherein at least one selected from the above GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist is included in an amount of 3% to 50% by weight based on the total weight of the microspheres.

9. In paragraph 1, A pharmaceutical composition wherein the microspheres further comprise a biocompatible polymer.

10. In paragraph 9, A pharmaceutical composition, wherein the biocompatible polymer is at least one selected from polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazine, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, copolymer of lactic acid and caprolactone, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and copolymer of lactic acid and amino acid.

11. In paragraph 9, A pharmaceutical composition wherein the biocompatible polymer is contained in an amount of 50 to 97 wt% based on the total weight of the microparticles.

12. In paragraph 1, A pharmaceutical composition further comprising one or more additives selected from a buffer, an isotonic agent, a preservative, and a pH adjusting agent.

13. In paragraph 9, A pharmaceutical composition wherein the microspheres comprise at least one selected from the GLP-1 receptor agonist, GIP / GLP-1 receptor agonist, and GLP-1 / GIP / GCG receptor triple agonist and the biocompatible polymer in a weight ratio of 1:1 to 50.

14. In paragraph 1, A pharmaceutical composition wherein the above microparticles remain stable for more than 6 months.

15. In paragraph 1, A pharmaceutical composition, wherein the above pharmaceutical composition is an injection.

Citation Information

Patent Citations

  • Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby

    KR100918092B1

  • The method of separating and purifying cellular components using non-covalent bond between a cucurbituril derivative and a guest compound and an apparatus using the same

    KR1020090109809A

  • Mask with replaceable filter

    KR1020210126331A

  • Method of automatically doffing the full bobbin packages from, and donning the empty bobbin tubes onto, the spindles of a preparatory spinning machine

    US4389840A

  • Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents

    US4530840A